Skip to content

Abivax

  • EN
  • FR
  • About Abivax
    • Our Mission
    • Company History
    • Our Leadership
    • Contact Us
  • Our Science
    • Novel MOA
    • Obefazimod
  • Our Research
  • Our Pipeline
  • Publications
  • Investors
    • Overview
    • Press Releases
    • News
    • Share Price
    • Investor Documents
    • General Meeting
    • Corporate Presentation
  • EN
  • FR

News & Events

Press Coverage

  • 2023
  • 2022
  • 2021
  • 2020
  • 2019

Mes actions

September 3, 2020

Abivax grimpe de près de 10% après les annonces

Bourse Direct

September 3, 2020

ABIVAX : en route vers la phase 3 pour l’ABX464

La Tribune

September 3, 2020

Abivax: résultats de maintenance favorables pour ABX464

BFM Bourse -TradingSat

September 3, 2020

CAC 40 : LA BOURSE DE PARIS ACHÈTE ELLE AUSSI LE PLAN DE RELANCE

TrialSite News

September 3, 2020

Abivax’s Phase 2a Clinical Trial Data Evidences ABX464 Effective Against Ulcerative Colitis

  • 1
  • …
  • 14
  • 15
  • 16
  • 17
  • 18
  • …
  • 46

References available upon request.

© 2025 All rights reserved by Abivax 07/2024 Privacy and Terms of Use
Consent Preferences
  • About Abivax
    • Our Mission
    • Company History
    • Our Leadership
    • Contact Us
  • Our Science
    • Novel MOA
    • Obefazimod
  • Our Research
  • Our Pipeline
  • Publications
  • Investors
    • Overview
    • Press Releases
    • News
    • Share Price
    • Investor Documents
    • General Meeting
    • Corporate Presentation
Contact Us
  • Follow us on Twitter
  • Follow us on LinkedIn